Evaluation of a Machine Learning-Based Prognostic Model for Unrelated Hematopoietic Cell Transplantation Donor Selection
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jun 01, 2018
- Source ID
- 10.1016/j.bbmt.2018.01.038
Entities
People
- David Loftus
- Jason Shelton
- Katharina Fleischhauer
- Katharine C Hsu
- Ljubomir Buturović
- Lyndal Hesterberg
- Lyssa Friedman
- Michael R Verneris
- Mike Haagenson
- Stephanie J. Lee
- Stephen R. Spellman
- Tao Wang
- Todd Woodring
Organizations
- Actinium Pharmaceuticals (United States)
- Amgen
- Angiocrine Bioscience (United States)
- Astellas Pharma (United States)
- AstraZeneca (United States)
- Atara Biotherapeutics, Inc.
- Bristol-Myers Squibb
- Celgene
- Chiron Corporation
- Fred Hutchinson Cancer Center
- Genzyme
- Gilead Sciences
- Health Resources and Services Administration
- HistoGenetics (United States)
- Incyte
- Janssen Scientific Affairs (United States)
- Jazz Pharmaceuticals
- Karyopharm Therapeutics (United States)
- Kite Pharma
- Medical College of Wisconsin
- Merck & Co.
- Miltenyi Biotec
- National Heart, Lung, and Blood Institute
- National Institute of Allergy and Infectious Diseases
- National Marrow Donor Program
- Office of Naval Research
- Otsuka Pharmaceutical
- Patient-Centered Outcomes Research Institute
- Pfizer
- Seagen
- Shire plc
- Spectrum Pharmaceuticals
- St. Baldrick's Foundation
- Swedish Orphan Biovitrum
- Takeda Oncology
- University of Minnesota